Dr. Anthony Schwartz, Chief Entrepreneur in Residence at Miletus Biotechnology, is a serial entrepreneur with almost 20 years of experience in biotechnology-based startup companies. Dr. Schwartz has founded at least 20 startups primarily focused on cancer, rare diseases, and aging, leading to large financings and FDA approval. He has significant expertise in cancer immunotherapies, particularly antisense, small molecules, and CART therapeutic modalities.

During his career, Dr. Schwartz has served in executive positions in several biotechnology companies. More recently, he was an entrepreneur in residence at Hibiscus BioVentures, which facilitated financings and launched several biotechnology companies. He helped establish the Mayflower BioVentures fund, which spearheaded laboratory-stage therapeutic assets from the Mayo Clinic into companies. Additionally, he serves as an advisor to the management teams and boards of numerous small biotechnology companies, including Primera Therapeutics, Sendero Biotechnology, Abvance Therapeutics, Matrix Biosciences, Morphiex Biotherapeutics, and VitaDao.

Dr. Schwartz received his Ph.D. in biomedical engineering from Colorado State University, with research focused on the immune system’s role in cancer, novel radiation therapies, and stem cells. He later became an NIH/NCI postdoctoral fellow, where he focused on CD47-based immunotherapies for cancer, which led to the launch of Morphiex Biotherapeutics. Dr. Schwartz has been published in multiple prestigious journals and holds patents on a class of drugs attenuating the immune system for treating cancer and diabetes. Finally, he is a professor at Johns Hopkins University, teaching a course on finance and how to launch a biotechnology company.